ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012

Authors/Task Force Members: John J.V. McMurray (Chairperson) (UK)*, Stamatis Adamopoulos (Greece), Stefan D. Anker (Germany), Angelo Auricchio (Switzerland), Michael Bohm (Germany), Kenneth Dickstein (Norway), Volkmar Falk (Switzerland), Gerasimos Filippatos (Greece), Cândida Fonseca (Portugal), Miguel Angel Gomez-Sanchez (Spain), Tiny Jaarsma (Sweden), Lars Kober (Denmark), Gregory Y.H. Lip (UK), Aldo Pietro Maggioni (Italy), Alexander Parkhomenko (Ukraine), Burkert M. Pieske (Austria), Bogdan A. Popescu (Romania), Per K. Ronnevik (Norway), Frans H. Rutten (The Netherlands), Juerg Schwitter (Switzerland), Petar Seferovic (Serbia), Janina Stepinska (Poland), Pedro T. Trindade (Switzerland), Adriaan A. Voors (The Netherlands), Faiez Zannad (France), Andreas Zeiher (Germany).

[1]  H. Figulla,et al.  Vasodilation by urapidil in the treatment of chronic congestive heart failure in addition to angiotensin-converting enzyme inhibitors is not beneficial: results of a placebo-controlled, double-blind study. , 1997, Journal of cardiac failure.

[2]  Stefano Ghio,et al.  Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. , 2008, Journal of the American College of Cardiology.

[3]  G. Steinbeck,et al.  OMEGA, a Randomized, Placebo-Controlled Trial to Test the Effect of Highly Purified Omega-3 Fatty Acids on Top of Modern Guideline-Adjusted Therapy After Myocardial Infarction , 2010, Circulation.

[4]  C. O’loughlin,et al.  Clinical deterioration in established heart failure: What is the value of BNP and weight gain in aiding diagnosis? , 2005, European journal of heart failure.

[5]  Michael Böhm,et al.  Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2010, The Lancet.

[6]  Gregory Y H Lip,et al.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.

[7]  K. Swedberg,et al.  Recall of lifestyle advice in patients recently hospitalised with heart failure: A EuroHeart Failure Survey analysis , 2007, European journal of heart failure.

[8]  J. Oss,et al.  PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .

[9]  M. Padeletti,et al.  Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. , 2007, Journal of the American College of Cardiology.

[10]  P. Ponikowski,et al.  EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. , 2006, European heart journal.

[11]  Peter Lindgren,et al.  Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary , 2007 .

[12]  Colin Simpson,et al.  Long-Term Trends in First Hospitalization for Heart Failure and Subsequent Survival Between 1986 and 2003: A Population Study of 5.1 Million People , 2009, Circulation.

[13]  J. McMurray,et al.  Do patients with suspected heart failure and preserved left ventricular systolic function suffer from “diastolic heart failure” or from misdiagnosis? A prospective descriptive study , 2000, BMJ : British Medical Journal.

[14]  Jeroen J. Bax,et al.  Results of the Predictors of Response to CRT (PROSPECT) Trial , 2008, Circulation.

[15]  P A Poole-Wilson,et al.  The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. , 2004, American heart journal.

[16]  F. Veglia,et al.  Catheter Ablation for the Treatment of Electrical Storm in Patients With Implantable Cardioverter-Defibrillators: Short- and Long-Term Outcomes in a Prospective Single-Center Study , 2008, Circulation.

[17]  Christopher M O'Connor,et al.  Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. , 2010, Journal of the American College of Cardiology.

[18]  K. Sliwa,et al.  Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy , 2010, European journal of heart failure.

[19]  P. Ponikowski,et al.  Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. , 2007, Journal of the American College of Cardiology.

[20]  S G Thompson,et al.  Incidence and aetiology of heart failure; a population-based study. , 1999, European heart journal.

[21]  D. DeMets,et al.  Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study , 2002, Circulation.

[22]  W. Gaasch,et al.  Left ventricular diastolic dysfunction and diastolic heart failure. , 2004, Annual review of medicine.

[23]  G. Guyatt,et al.  Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis. , 2004, Journal of cardiac failure.

[24]  L. Levin,et al.  Nurse-led heart failure clinics improve survival and self-care behaviour in patients with heart failure: results from a prospective, randomised trial. , 2003, European heart journal.

[25]  J. Kirkpatrick,et al.  Echocardiography in heart failure: applications, utility, and new horizons. , 2007, Journal of the American College of Cardiology.

[26]  Inger Ekman,et al.  Population Impact of Heart Failure and the Most Common Forms of Cancer: A Study of 1 162 309 Hospital Cases in Sweden (1988 to 2004) , 2010, Circulation. Cardiovascular quality and outcomes.

[27]  R. McKelvie,et al.  The 2011 Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care. , 2011, The Canadian journal of cardiology.

[28]  Helmut Baumgartner,et al.  ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). , 2010, European heart journal.

[29]  S. De Geest,et al.  Adherence to Long-Term Therapies: Evidence for Action , 2003, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.

[30]  N. Paul,et al.  Perioperative β-Blockers : Use With Caution Perioperative β Blockers in Patients Having Non-Cardiac Surgery : A Meta-Analysis , 2010 .

[31]  Ralph D'Agostino,et al.  Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. , 2004, The New England journal of medicine.

[32]  W. Paulus,et al.  Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. , 2011, European heart journal.

[33]  D. Sin,et al.  Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. , 2005, Proceedings of the American Thoracic Society.

[34]  S. Yusuf,et al.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.

[35]  Elizabeth Avery,et al.  Self-management counseling in patients with heart failure: the heart failure adherence and retention randomized behavioral trial. , 2010, JAMA.

[36]  Wang Ch,et al.  Effect of verapamil in elderly patients with left ventricular diastolic dysfunction as a cause of congestive heart failure. , 2002 .

[37]  M. Borggrefe,et al.  Intrathoracic Impedance Monitoring, Audible Patient Alerts, and Outcome in Patients With Heart Failure , 2011, Circulation.

[38]  Vic Hasselblad,et al.  Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of randomized clinical trials. , 2005, JAMA.

[39]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[40]  K. Bailey,et al.  Clinical criteria and biochemical markers for the detection of systolic dysfunction. , 2000, Journal of cardiac failure.

[41]  Piotr Ponikowski,et al.  2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, European heart journal.

[42]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[43]  J. Ornato,et al.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .

[44]  B. Chow,et al.  Recent advances in cardiac imaging for patients with heart failure. , 2011, Current opinion in cardiology.

[45]  S. Yusuf,et al.  Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. , 1995, JAMA.

[46]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[47]  P. Poole‐Wilson,et al.  Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care , 1997, The Lancet.

[48]  D. Renlund,et al.  Consensus statement: Palliative and supportive care in advanced heart failure. , 2004, Journal of cardiac failure.

[49]  A. Cohen-Solal,et al.  Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. , 2007, Journal of the American College of Cardiology.

[50]  T. Hutchinson,et al.  Interobserver agreement by auscultation in the presence of a third heart sound in patients with congestive heart failure. , 1987, Chest.

[51]  K. Khunti,et al.  Accuracy of a 12‐lead electrocardiogram in screening patients with suspected heart failure for open access echocardiography: a systematic review and meta‐analysis , 2004, European journal of heart failure.

[52]  E. Sacanella,et al.  The Effect of Controlled Drinking in Alcoholic Cardiomyopathy , 2002, Annals of Internal Medicine.

[53]  J. McMurray,et al.  How much responsibility should heart failure nurses take? , 2005, European journal of heart failure.

[54]  P. Ponikowski,et al.  Overview and meta-analysis of randomised trials of amiodarone in chronic heart failure. , 1998, International journal of cardiology.

[55]  M. Weir,et al.  The Cardiac Arrhythmia Suppression Trial Investigators: Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression After Myocardial Infarction. , 1990 .

[56]  J. Madias.  Why Recording of an Electrocardiogram Should be Required in Every Inpatient and Outpatient Encounter of Patients with Heart Failure , 2011, Pacing and clinical electrophysiology : PACE.

[57]  C. McHorney,et al.  The MOS 36‐Item Short‐Form Health Survey (SF‐36): II. Psychometric and Clinical Tests of Validity in Measuring Physical and Mental Health Constructs , 1993, Medical care.

[58]  Barry R. Davis,et al.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. , 2000, JAMA.

[59]  T. Killip,et al.  Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. , 1967, The American journal of cardiology.

[60]  P. Poole‐Wilson,et al.  Role of skeletal muscle in the syndrome of chronic heart failure. , 1996, Journal of molecular and cellular cardiology.

[61]  A. Rigby,et al.  Effect of a community heart failure clinic on uptake of β blockers by patients with obstructive airways disease and heart failure , 2005, Heart.

[62]  A. Camm,et al.  Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure , 2009 .

[63]  M. Keller,et al.  A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. , 1997, The New England journal of medicine.

[64]  Simon Stewart,et al.  Financial aspects of heart failure programs of care , 2005, European journal of heart failure.

[65]  Roberto Marchioli,et al.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. , 1999 .

[66]  Bertram Pitt,et al.  Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II , 2000, The Lancet.

[67]  H. Calkins,et al.  HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). , 2011, Heart rhythm.

[68]  S G Thompson,et al.  Survival of patients with a new diagnosis of heart failure: a population based study , 2000, Heart.

[69]  A. Hoes,et al.  Clinical utility of three B-type natriuretic peptide assays for the initial diagnostic assessment of new slow-onset heart failure. , 2011, Journal of cardiac failure.

[70]  Akshay S. Desai,et al.  Patient expectations from implantable defibrillators to prevent death in heart failure. , 2010, Journal of cardiac failure.

[71]  Johan Herlitz,et al.  Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .

[72]  M. Piepoli,et al.  Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH) , 2004, BMJ : British Medical Journal.

[73]  B. Pitt,et al.  Eplerenone , a Selective Aldosterone Blocker , in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[74]  J. Bigger,et al.  Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. , 1997, The New England journal of medicine.

[75]  E. Retyk,et al.  Subanalyses of secondary prevention implantable cardioverter-defibrillator trials: antiarrhythmics versus implantable defibrillators (AVID), Canadian Implantable Defibrillator Study (CIDS), and Cardiac Arrest Study Hamburg (CASH). , 2004, Current opinion in cardiology.

[76]  N. Freemantle,et al.  Clinical trials update from the American Heart Association meeting: ACORN‐CSD, primary care trial of chronic disease management, PEACE, CREATE, SHIELD, A‐HeFT, GEMINI, vitamin E meta‐analysis, ESCAPE, CARP, and SCD‐HeFT cost‐effectiveness study , 2005, European journal of heart failure.

[77]  M. A. Spiteri,et al.  RELIABILITY OF ELICITING PHYSICAL SIGNS IN EXAMINATION OF THE CHEST , 1988, The Lancet.

[78]  R. Cappato,et al.  Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). , 2000, Circulation.

[79]  P. Poole‐Wilson,et al.  Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. , 2002, International journal of cardiology.

[80]  W. Peacock.  Morphine for Acute Decompensated Heart Failure: Valuable Adjunct or a Historical Remnant? , 2005 .

[81]  L. Stevenson,et al.  The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. , 1989, JAMA.

[82]  S. Yusuf,et al.  Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction. , 2001, Journal of the American College of Cardiology.

[83]  C. Yancy,et al.  Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. , 2006, Journal of the American College of Cardiology.

[84]  John G F Cleland,et al.  Predictors of fatal and non‐fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A‐1, high‐sensitivity C‐reactive peptide and N‐terminal pro B‐type natriuretic peptide , 2009, European journal of heart failure.

[85]  R. Arena,et al.  PDE5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function, Cardiac Geometry, and Clinical Status in Patients With Stable Systolic Heart Failure: Results of a 1-Year, Prospective, Randomized, Placebo-Controlled Study , 2011, Circulation. Heart failure.

[86]  M. Cuffe.  Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. , 2002, JAMA.

[87]  J. Sanchís,et al.  Non-invasive ventilation , 2002, Thorax.

[88]  M. Cowie,et al.  The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: Results of the UK natriuretic peptide study , 2005, European journal of heart failure.

[89]  P. Sobotka,et al.  Ultrafiltration is associated with fewer rehospitalizations than continuous diuretic infusion in patients with decompensated heart failure: results from UNLOAD. , 2010, Journal of cardiac failure.

[90]  J. McMurray,et al.  Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation. , 1989, Journal of cardiovascular pharmacology.

[91]  U. Elkayam,et al.  Intravenous Nitroglycerin in the Treatment of Decompensated Heart Failure: Potential Benefits and Limitations , 2004, Journal of cardiovascular pharmacology and therapeutics.

[92]  Richard Sutton,et al.  Guidelines for cardiac pacing and cardiac resynchronization therapy. The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association. , 2007, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[93]  W. Cherng,et al.  EFFECT OF VERAPAMIL IN ELDERLY PATIENTS WITH LEFT VENTRICULAR DIASTOLIC DYSFUNCTION AS A CAUSE OF CONGESTIVE HEART FAILURE , 2002, International journal of clinical practice.

[94]  A. Laupacis,et al.  Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study , 2004, The Lancet.

[95]  K. Dracup,et al.  Usefulness of a history of tobacco and alcohol use in predicting multiple heart failure readmissions among veterans. , 2000, The American journal of cardiology.

[96]  S. Nattel,et al.  Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. , 1991, Circulation.

[97]  M. Guglin,et al.  Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. , 2007, Journal of the American College of Cardiology.

[98]  Bertram Pitt,et al.  Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction , 1996, The Lancet.

[99]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[100]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[101]  S. Ebrahim,et al.  Exercise based rehabilitation for heart failure. , 2004, The Cochrane database of systematic reviews.

[102]  A. Skene,et al.  Pioglitazone Use and Heart Failure in Patients With Type 2 Diabetes and Preexisting Cardiovascular Disease , 2007, Diabetes Care.

[103]  Y. Sheikine,et al.  Integrated PET/CT in the assessment of etiology and viability in ischemic heart failure , 2008, Current heart failure reports.

[104]  M. Metra,et al.  Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. , 2002, Journal of the American College of Cardiology.

[105]  Jeroen J. Bax,et al.  The effects of right ventricular apical pacing on ventricular function and dyssynchrony implications for therapy. , 2009, Journal of the American College of Cardiology.

[106]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[107]  A. Philip,et al.  History, definition, and classification of heart failure , 1997 .

[108]  M. Janse,et al.  Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials , 1997, The Lancet.

[109]  J. McMurray,et al.  Importance of heart failure as a cause of death. Changing contribution to overall mortality and coronary heart disease mortality in Scotland 1979-1992. , 1998, European heart journal.

[110]  Recommendations for exercise training in chronic heart failure patients. , 2001, European heart journal.

[111]  A. Arai,et al.  Assessment of cardiac ischaemia and viability: role of cardiovascular magnetic resonance , 2011, European heart journal.

[112]  Arno W. Hoes,et al.  The Diagnostic Value of Physical Examination and Additional Testing in Primary Care Patients With Suspected Heart Failure , 2011, Circulation.

[113]  J. Cleland,et al.  Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? , 2003, Journal of the American College of Cardiology.

[114]  S Capewell,et al.  More ‘malignant’ than cancer? Five‐year survival following a first admission for heart failure , 2001, European journal of heart failure.

[115]  W. Levy,et al.  Establishing prognosis in heart failure: a multimarker approach. , 2011, Progress in cardiovascular diseases.

[116]  Harlan M Krumholz,et al.  What works in chronic care management: the case of heart failure. , 2009, Health affairs.

[117]  B. Massie,et al.  Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study. , 1993, Journal of the American College of Cardiology.

[118]  P. Vandervoort,et al.  Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. , 2002, Journal of the American College of Cardiology.

[119]  A. Hoes,et al.  Clinical epidemiology of heart failure , 2007, Heart.

[120]  T. Huber,et al.  Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients , 2012 .

[121]  Creighton Am.  Letter: ICRF 159. , 1974 .

[122]  M. Kruszewski,et al.  Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. , 2008, European heart journal.

[123]  A. Moss,et al.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. , 1996, The New England journal of medicine.

[124]  M. Laakso,et al.  Guidelines on Diabetes, Pre-Diabetes, and Cardiovascular Diseases: Executive Summary , 2007 .

[125]  G. Gazelle,et al.  A systematic meta-analysis of the efficacy and heterogeneity of disease management programs in congestive heart failure. , 2006, Journal of cardiac failure.

[126]  Shah Ebrahim,et al.  [European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)]. , 2013, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[127]  M. Domanski,et al.  A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. , 2001, The New England journal of medicine.

[128]  Alan S Maisel,et al.  Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.

[129]  F. Rutten,et al.  Clinical evaluation of geriatric outpatients with suspected heart failure: value of symptoms, signs, and additional tests , 2011, European journal of heart failure.

[130]  Stefan D Anker,et al.  Telemedicine and remote management of patients with heart failure , 2011, The Lancet.

[131]  J. Cohn,et al.  Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. , 1997, Circulation.

[132]  H. Dargie,et al.  Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial , 2001, The Lancet.

[133]  N. Lakkis,et al.  Assessment of the American Society of Echocardiography-European Association of Echocardiography guidelines for diastolic function in patients with depressed ejection fraction: an echocardiographic and invasive haemodynamic study. , 2011, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[134]  S. Russell,et al.  Advanced heart failure treated with continuous-flow left ventricular assist device. , 2009, The New England journal of medicine.

[135]  M. Quiñones,et al.  Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. , 1997, Journal of the American College of Cardiology.

[136]  M. Lauer,et al.  Survival after aortic valve replacement for severe aortic stenosis with low transvalvular gradients and severe left ventricular dysfunction. , 2002, Journal of the American College of Cardiology.

[137]  A. Camm,et al.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, European heart journal.

[138]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[139]  M. Pfeffer,et al.  Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program , 2009, European journal of heart failure.

[140]  P. Hildebrandt,et al.  Combination Therapy with Metolazone and Loop Diuretics in Outpatients with Refractory Heart Failure: An Observational Study and Review of the Literature , 2005, Cardiovascular Drugs and Therapy.

[141]  M. Pfeffer,et al.  Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. , 2007, Journal of the American College of Cardiology.

[142]  Adrian F Hernandez,et al.  Diuretic strategies in patients with acute decompensated heart failure. , 2011, The New England journal of medicine.

[143]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure , 1986 .

[144]  C. Gullion,et al.  The incidence of congestive heart failure in type 2 diabetes: an update. , 2004, Diabetes care.

[145]  W. Stevenson,et al.  Management of atrial fibrillation in patients with heart failure. , 2007, Heart rhythm.

[146]  K. Dracup,et al.  A closer look at compliance research in heart failure patients in the last decade. , 2000, Progress in cardiovascular nursing.

[147]  Sumit R. Majumdar,et al.  Treatment of Type 2 Diabetes and Outcomes in Patients With Heart Failure: A Nested Case–Control Study From the U.K. General Practice Research Database , 2010, Diabetes Care.

[148]  J. Cleland,et al.  Telemonitoring or structured telephone support programmes for patients with chronic heart failure: systematic review and meta-analysis , 2007, BMJ : British Medical Journal.

[149]  K. Dickstein,et al.  Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial , 2002, The Lancet.

[150]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.

[151]  H Ector,et al.  Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. , 2001, The New England journal of medicine.

[152]  Hans L Hillege,et al.  Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). , 2008, Archives of internal medicine.

[153]  G. Aurigemma,et al.  Clinical practice. Diastolic heart failure. , 2004, The New England journal of medicine.

[154]  S. Solomon,et al.  Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED‐HF): a Phase III, anaemia correction, morbidity–mortality trial , 2009, European journal of heart failure.

[155]  N. Hollenberg,et al.  Literature alert , 2002 .

[156]  Simon Stewart,et al.  Effects of a multidisciplinary, home-based intervention on planned readmissions and survival among patients with chronic congestive heart failure: a randomised controlled study , 1999, The Lancet.

[157]  M. Gheorghiade,et al.  Rationale and design of the multicentre, randomized, double‐blind, placebo‐controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) , 2011, European journal of heart failure.

[158]  N. Freemantle,et al.  Clinical trials update and cumulative meta‐analyses from the American College of Cardiology: WATCH, SCD‐HeFT, DINAMIT, CASINO, INSPIRE, STRATUS‐US, RIO‐Lipids and cardiac resynchronisation therapy in heart failure , 2004, European journal of heart failure.

[159]  How to diagnose diastolic heart failure. European Study Group on Diastolic Heart Failure. , 1998, European heart journal.

[160]  Anna Strömberg,et al.  Self‐care management of heart failure: practical recommendations from the Patient Care Committee of the Heart Failure Association of the European Society of Cardiology , 2011, European journal of heart failure.

[161]  Hugh Tunstall-Pedoe,et al.  Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population , 1997, The Lancet.

[162]  R. Cody,et al.  Discharge Education Improves Clinical Outcomes in Patients With Chronic Heart Failure , 2005, Circulation.

[163]  R. Hershberger,et al.  Pharmacologic and hemodynamic effects of combined beta-agonist stimulation and phosphodiesterase inhibition in the failing human heart. , 1995, Chest.

[164]  Jose Luis Zamorano,et al.  Stress echocardiography expert consensus statement: European Association of Echocardiography (EAE) (a registered branch of the ESC). , 2008, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[165]  P. Poole‐Wilson,et al.  Symptoms in patients with heart failure are prognostic predictors: insights from COMET. , 2005, Journal of cardiac failure.

[166]  Eva Pietrzak,et al.  A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. , 2004, Archives of internal medicine.

[167]  M. Laakso,et al.  Effect of valsartan on the incidence of diabetes and cardiovascular events. , 2010, The New England journal of medicine.

[168]  B. Billah,et al.  B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. , 2010, Archives of internal medicine.

[169]  P. Ponikowski,et al.  Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology , 2009, European journal of heart failure.

[170]  Harlan M Krumholz,et al.  Renal impairment and outcomes in heart failure: systematic review and meta-analysis. , 2006, Journal of the American College of Cardiology.

[171]  E. Fisher,et al.  Should aspirin be continued in patients started on warfarin? , 2004, Journal of General Internal Medicine.

[172]  C. T. Layton,et al.  Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia , 1996 .

[173]  N Engl,et al.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. , 1997, Circulation.

[174]  S. Connolly,et al.  Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study. , 2000, European heart journal.

[175]  Alan S Maisel,et al.  How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study. , 2006, American heart journal.

[176]  Z. Rumboldt,et al.  Diuretic effects of furosemide infusion versus bolus injection in congestive heart failure. , 1998, International journal of clinical pharmacology research.

[177]  V. Roger.  Epidemiology of Heart Failure , 2013, Circulation research.

[178]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure. Results of a Veterans Administration Cooperative Study , 1987 .

[179]  J. Nicholl,et al.  Noninvasive ventilation in acute cardiogenic pulmonary edema. , 2008, The New England journal of medicine.

[180]  K. Swedberg,et al.  Guidelines for the diagnosis and treatment of chronic heart failure. , 2001, European heart journal.

[181]  R. McKelvie,et al.  Practical recommendations for the use of ACE inhibitors, beta‐blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice , 2005, European journal of heart failure.

[182]  Shu-lin Wu,et al.  Prophylactic Use of an Implantable Cardioverter-defibrillator after Acute Myocardial Infarction , 2005 .

[183]  R. Fernandez,et al.  Noninvasive ventilation in acute cardiogenic pulmonary edema: systematic review and meta-analysis. , 2005, JAMA.

[184]  A. Kocheril,et al.  Intravenous Vasodilator Therapy in Congestive Heart Failure , 2003, Drugs & aging.

[185]  Otto Kamp,et al.  Lenient versus strict rate control in patients with atrial fibrillation. , 2010, The New England journal of medicine.

[186]  J. Rouleau,et al.  Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. , 2003, JAMA.

[187]  A. DeMaria,et al.  Comparative effects of morphine, meperidine and pentazocine on cardiocirculatory dynamics in patients with acute myocardial infarction. , 1976, The American journal of medicine.

[188]  M. Pfeffer,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial , 2003, The Lancet.

[189]  A. Cohen-Solal,et al.  Executive summary of the Position Paper of the Working Group on Cardiac Rehabilitation and Exercise Physiology of the European Society of Cardiology (ESC): core components of cardiac rehabilitation in chronic heart failure , 2005, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[190]  J. McMurray,et al.  Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.

[191]  L. Tan,et al.  DETRIMENTAL HAEMODYNAMIC EFFECTS OF CYCLIZINE IN HEART FAILURE , 1988, The Lancet.

[192]  C. Fonseca.  Diagnosis of heart failure in primary care , 2006, Heart Failure Reviews.

[193]  Munir Pirmohamed,et al.  Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology , 2011, European journal of heart failure.

[194]  A. Wardley,et al.  Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring , 2009, British Journal of Cancer.

[195]  A. Camm,et al.  Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT , 1997, The Lancet.

[196]  J. H. Patterson,et al.  Executive Summary Executive Summary : HFSA 2010 Comprehensive Heart Failure Practice Guideline , 2022 .

[197]  T. Therneau,et al.  Hospitalizations after heart failure diagnosis a community perspective. , 2009, Journal of the American College of Cardiology.

[198]  R. Vasan,et al.  Epidemiology and clinical course of heart failure with preserved ejection fraction , 2011, European journal of heart failure.

[199]  U. Siebert,et al.  Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. , 2009, The New England journal of medicine.

[200]  Paul J Mills,et al.  Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. , 2006, Journal of the American College of Cardiology.

[201]  D. Mancini,et al.  Exertional Fatigue Due to Skeletal Muscle Dysfunction in Patients With Heart Failure , 1993, Circulation.

[202]  Jeroen J. Bax,et al.  Assessment of Myocardial Viability in Patients with Heart Failure* , 2007, Journal of Nuclear Medicine.

[203]  J. Cleland,et al.  Clinical trials update from the European Society of Cardiology Congress 2007: 3CPO, ALOFT, PROSPECT and statins for heart failure , 2007, European journal of heart failure.

[204]  Sasha Shepperd,et al.  Discharge planning from hospital to home. , 2010, The Cochrane database of systematic reviews.

[205]  R. Vasan,et al.  The progression from hypertension to congestive heart failure. , 1996, JAMA.

[206]  L. Deckelbaum,et al.  Effect of nesiritide in patients with acute decompensated heart failure. , 2011, The New England journal of medicine.

[207]  C. Huerta,et al.  Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population , 2006, Heart.

[208]  Andrea Giordano,et al.  Sleep and Exertional Periodic Breathing in Chronic Heart Failure: Prognostic Importance and Interdependence , 2005, Circulation.

[209]  J. McMurray,et al.  Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. , 2004, Journal of the American College of Cardiology.

[210]  E. Schmid,et al.  Introduction and epidemiology , 2018, ESC CardioMed.

[211]  Jeroen J. Bax,et al.  Recent developments in heart failure imaging. , 2010, JACC. Cardiovascular imaging.

[212]  S. Katz,et al.  Anemia in Chronic Heart Failure: Prevalence, Etiology, Clinical Correlates, and Treatment Options , 2006, Circulation.

[213]  K. Kuck,et al.  Primary Prevention of Sudden Cardiac Death in Idiopathic Dilated Cardiomyopathy: The Cardiomyopathy Trial (CAT) , 2002, Circulation.

[214]  Piotr Pruszczyk,et al.  Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism , 2008 .

[215]  M. Pfeffer,et al.  Adverse mortality effect of central sympathetic inhibition with sustained‐release moxonidine in patients with heart failure (MOXCON) , 2003, European journal of heart failure.

[216]  Volkmar Falk,et al.  Guidelines on Myocardial Revascularization the Task Force on Myocardial Revascularization of the European Society of Cardiology (esc) and the European Association for Cardio-thoracic Surgery (eacts) Developed with the Special Contribution of the European Association for Percutaneous Cardiovascular I , 2022 .

[217]  M. Bristow,et al.  Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. , 2001, International journal of cardiology.

[218]  O. Benavente,et al.  Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation , 1999, Annals of Internal Medicine.

[219]  Jeroen J. Bax,et al.  2010 Focused Update of ESC Guidelines on device therapy in heart failure , 2010, European journal of heart failure.

[220]  O M Jolobe,et al.  Echocardiography in chronic heart failure in the community. , 1993, The Quarterly journal of medicine.

[221]  Gianni Tognoni,et al.  Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). , 2008, Journal of the American College of Cardiology.

[222]  J. Zamorano,et al.  European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 1: aortic and pulmonary regurgitation (native valve disease). , 2010, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[223]  L. Tavazzi,et al.  Nationwide survey on acute heart failure in cardiology ward services in Italy. , 2005, European heart journal.

[224]  Salim Yusuf,et al.  Predictors of mortality and morbidity in patients with chronic heart failure. , 2006, European heart journal.

[225]  T. Marwick,et al.  Exercise training for patients with heart failure: a systematic review of factors that improve mortality and morbidity. , 2004, The American journal of medicine.

[226]  V. Somers,et al.  Dopamine depresses minute ventilation in patients with heart failure. , 1998, Circulation.

[227]  H. Black,et al.  Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. , 1990, The American journal of cardiology.

[228]  P. Poole‐Wilson,et al.  Factors determining symptoms in heart failure: comparison of fast and slow exercise tests. , 1986, British heart journal.

[229]  P. Ponikowski,et al.  Ferric carboxymaltose in patients with heart failure and iron deficiency. , 2009, The New England journal of medicine.

[230]  R Dietz,et al.  Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. , 2000, JAMA.

[231]  J. Daubert,et al.  Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association. , 2007, European heart journal.

[232]  J. Rouleau,et al.  Navigating the Crossroads of Coronary Artery Disease and Heart Failure , 2006, Circulation.

[233]  E. Fleck,et al.  How we perform myocardial perfusion with cardiovascular magnetic resonance. , 2007, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[234]  J. Zamorano,et al.  European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease). , 2010, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[235]  Arturo Evangelista,et al.  European Association of Echocardiography recommendations for training, competence, and quality improvement in echocardiography. , 2009, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[236]  A. Strömberg.  The crucial role of patient education in heart failure , 2005, European journal of heart failure.

[237]  J. Remes,et al.  Validity of clinical diagnosis of heart failure in primary health care. , 1991, European heart journal.

[238]  W. Ghali,et al.  Outcomes of cardiac resynchronization therapy in patients with versus those without atrial fibrillation: a systematic review and meta-analysis. , 2011, Heart rhythm.

[239]  D. DeMets,et al.  Factors Associated With Outcome in Heart Failure With Preserved Ejection FractionClinical Perspective , 2011 .

[240]  C. O’loughlin,et al.  Fluid restriction in the management of decompensated heart failure: no impact on time to clinical stability. , 2007, Journal of cardiac failure.

[241]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[242]  T. Moreland,et al.  A comparison of digoxin, diltiazem and their combination in the treatment of atrial fibrillation. , 1988, European heart journal.

[243]  S. Solomon,et al.  GUIDELINES AND STANDARDS , 2010 .

[244]  Otto Kamp,et al.  EAE/ASE recommendations for image acquisition and display using three-dimensional echocardiography. , 2012, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[245]  Gissi-Hf Investigators.  Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[246]  K. Swedberg,et al.  Decreasing one-year mortality and hospitalization rates for heart failure in Sweden; Data from the Swedish Hospital Discharge Registry 1988 to 2000. , 2003, European heart journal.

[247]  Adrian V. Hernández,et al.  Thiazolidinediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus , 2011, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[248]  J. Ornato,et al.  ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidel , 2006, European heart journal.

[249]  K. Dickstein,et al.  How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. , 2007, European heart journal.

[250]  P Barton,et al.  Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. , 2009, Health technology assessment.

[251]  M. Nieminen,et al.  Characteristics, outcomes, and predictors of 1-year mortality in patients hospitalized for acute heart failure. , 2006, European heart journal.

[252]  P. Ponikowski,et al.  Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. , 2010, Journal of the American College of Cardiology.

[253]  J. McMurray,et al.  Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction , 1996, BMJ.

[254]  D. Thompson,et al.  Disease management programmes for older people with heart failure: crucial characteristics which improve post-discharge outcomes. , 2006, European heart journal.

[255]  Manesh R. Patel,et al.  ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR 2006 appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging. A report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group. , 2006, Journal of the American College of Radiology : JACR.

[256]  A. Camm,et al.  Mortality in Patients After a Recent Myocardial Infarction: A Randomized, Placebo-Controlled Trial of Azimilide Using Heart Rate Variability for Risk Stratification , 2004, Circulation.

[257]  G R Sutherland,et al.  Assessing diagnosis in heart failure: which features are any use? , 1997, QJM : monthly journal of the Association of Physicians.

[258]  P. Ponikowski,et al.  Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. , 2007, Journal of the American College of Cardiology.

[259]  Finn Gustafsson,et al.  2010 Focused Update of ESC Guidelines on Device Therapy in Heart Failure , 2011 .

[260]  W. Urbaszek.  [Definition and classification of heart failure]. , 1991, Zeitschrift fur Kardiologie.

[261]  J. Cleland,et al.  Which components of heart failure programmes are effective? A systematic review and meta‐analysis of the outcomes of structured telephone support or telemonitoring as the primary component of chronic heart failure management in 8323 patients: Abridged Cochrane Review , 2011, European journal of heart failure.

[262]  E. Nagel,et al.  Acute adverse reactions to gadolinium-based contrast agents in CMR: multicenter experience with 17,767 patients from the EuroCMR Registry. , 2011, JACC. Cardiovascular imaging.

[263]  G. D. De Keulenaer,et al.  Diastolic heart failure: a separate disease or selection bias? , 2007, Progress in cardiovascular diseases.

[264]  W Frank Peacock,et al.  State of the art: Using natriuretic peptide levels in clinical practice , 2008, European journal of heart failure.

[265]  M. Pfeffer,et al.  Which Inhibitor of the Renin–Angiotensin System Should Be Used in Chronic Heart Failure and Acute Myocardial Infarction? , 2004, Circulation.

[266]  R. F. Kelly,et al.  Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure. , 2002, The American journal of medicine.

[267]  E. Barrett-Connor,et al.  Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). , 2005, The American journal of cardiology.

[268]  T. Chalmers,et al.  Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration , 1994, The Lancet.

[269]  John L Sapp,et al.  Cardiac-resynchronization therapy for mild-to-moderate heart failure. , 2010, The New England journal of medicine.

[270]  Peter C Austin,et al.  Outcome of heart failure with preserved ejection fraction in a population-based study. , 2006, The New England journal of medicine.

[271]  G. Sutherland,et al.  Patient Selection and Echocardiographic Assessment of Dyssynchrony in Cardiac Resynchronization Therapy Crt: from Origins to Routine Clinical Practice Selection of Candidates in Crt Clinical Trials Defining Response to Therapy Contemporary Reviews in Cardiovascular Medicine , 2022 .

[272]  Michael Weis,et al.  Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. , 2008, European heart journal.

[273]  D. DeMets,et al.  Factors Associated With Outcome in Heart Failure With Preserved Ejection Fraction: Findings From the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-PRESERVE) , 2011, Circulation. Heart failure.

[274]  R. Wachter,et al.  Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial , 2011, European journal of heart failure.

[275]  P. Poole‐Wilson,et al.  Exercise Intolerance in Adult Congenital Heart Disease: Comparative Severity, Correlates, and Prognostic Implication , 2005, Circulation.

[276]  Simon Capewell,et al.  The current cost of heart failure to the National Health Service in the UK , 2002, European journal of heart failure.

[277]  K. Channer,et al.  Combination diuretic treatment in severe heart failure: a randomised controlled trial. , 1994, British heart journal.

[278]  S. Solomon,et al.  Albuminuria in chronic heart failure: prevalence and prognostic importance , 2009, The Lancet.

[279]  Ajay M Shah,et al.  In search of new therapeutic targets and strategies for heart failure: recent advances in basic science , 2011, The Lancet.

[280]  J. Cohn,et al.  Effect of Enalapril, Hydralazine Plus Isosorbide Dinitrate, and Prazosin on Hospitalization in Patients With Chronic Congestive Heart Failure , 1993, Circulation.

[281]  William Stewart,et al.  Recommendations for chamber quantification. , 2006, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[282]  P. Poole‐Wilson,et al.  Relation of pathophysiologic mechanisms to outcome in heart failure. , 1993, Journal of the American College of Cardiology.

[283]  Christopher M O'Connor,et al.  Coronary bypass surgery with or without surgical ventricular reconstruction. , 2009, The New England journal of medicine.

[284]  Helmut Baumgartner,et al.  Guidelines on the management of valvular heart disease The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology , 2007 .

[285]  G. Tognoni,et al.  The prognostic influence of chronic obstructive pulmonary disease in patients hospitalised for chronic heart failure , 2007, European journal of heart failure.

[286]  P. Tchou,et al.  Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. , 2007, The New England journal of medicine.

[287]  Magdi H Yacoub,et al.  Left ventricular assist device and drug therapy for the reversal of heart failure. , 2006, The New England journal of medicine.

[288]  D. Brutsaert.  Diastolic heart failure: perception of the syndrome and scope of the problem. , 2006, Progress in cardiovascular diseases.

[289]  R. Arena,et al.  Cardiopulmonary exercise testing is a core assessment for patients with heart failure. , 2011, Congestive heart failure.

[290]  E. Wouters,et al.  Striking similarities in systemic factors contributing to decreased exercise capacity in patients with severe chronic heart failure or COPD. , 2003, Chest.

[291]  N. Freemantle,et al.  Clinical trials update from the American Heart Association: REPAIR‐AMI, ASTAMI, JELIS, MEGA, REVIVE‐II, SURVIVE, and PROACTIVE , 2006, European journal of heart failure.

[292]  Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study. , 1993, Journal of the American College of Cardiology.

[293]  E. H. Skinner,et al.  Diseases of the Heart , 1936, The Indian Medical Gazette.

[294]  Michael Böhm,et al.  Kommentar zu den ESC-Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 , 2008, European journal of heart failure.

[295]  Hugh Calkins,et al.  Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. , 2004, The New England journal of medicine.

[296]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice: executive summary. , 2007, Atherosclerosis.

[297]  André Lamy,et al.  F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). , 2007, Journal of the American College of Cardiology.

[298]  W John Boscardin,et al.  Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. , 2005, JAMA.

[299]  J. Spertus,et al.  Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. , 2000, Journal of the American College of Cardiology.

[300]  Jeroen J. Bax,et al.  ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation , 2012 .

[301]  Karl Swedberg,et al.  Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. , 2008, European heart journal.

[302]  K. Chacko.  AHA Medical/Scientific Statement: 1994 revisions to classification of functional capacity and objective assessment of patients with diseases of the heart. , 1995, Circulation.

[303]  O. Alfieri,et al.  Guidelines on the management of valvular heart disease (version 2012). , 2012, European heart journal.

[304]  F. Rutten,et al.  Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. , 2005, European heart journal.

[305]  Markolf Hanefeld,et al.  Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial , 2010, European heart journal.

[306]  J. Pell,et al.  Evidence of Improving Prognosis in Heart Failure: Trends in Case Fatality in 66 547 Patients Hospitalized Between 1986 and 1995 , 2000, Circulation.

[307]  Keyur B Shah,et al.  Implantable Mechanical Circulatory Support: Demystifying Patients With Ventricular Assist Devices and Artificial Hearts , 2011, Clinical cardiology.

[308]  Mike Kirby,et al.  Guidelines on the management of cardiovascular diseases during pregnancy The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology ( ESC ) , 2011 .

[309]  F. Tristani,et al.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.

[310]  G. Beller,et al.  SPECT Imaging for Detecting Coronary Artery Disease and Determining Prognosis by Noninvasive Assessment of Myocardial Perfusion and Myocardial Viability , 2011, Journal of cardiovascular translational research.

[311]  John Mullooly,et al.  Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. , 2003, The New England journal of medicine.

[312]  C. Lang,et al.  Effect of Erythropoietin on Exercise Capacity in Patients With Moderate to Severe Chronic Heart Failure , 2003, Circulation.

[313]  P. Raskin,et al.  Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. , 2004, JAMA.

[314]  Abdissa Negassa,et al.  Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study , 2003, The Lancet.

[315]  J. McMurray,et al.  Clinical practice. Systolic heart failure. , 2010, The New England journal of medicine.

[316]  G. Diamond,et al.  Correlative classification of clinical and hemodynamic function after acute myocardial infarction. , 1977, The American journal of cardiology.

[317]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[318]  J. Tijssen,et al.  A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? , 2008, European heart journal.

[319]  M. Naughton.  The link between obstructive sleep apnea and heart failure: Underappreciated opportunity for treatment , 2005, Current cardiology reports.

[320]  M. Chung,et al.  Aggregate national experience with the wearable cardioverter-defibrillator: event rates, compliance, and survival. , 2010, Journal of the American College of Cardiology.

[321]  Henry Krum,et al.  Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study , 2011, European journal of heart failure.

[322]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[323]  Robert N. Doughty,et al.  The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. , 2011, European heart journal.

[324]  Salim Yusuf,et al.  Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients , 2000, The Lancet.

[325]  M. Cazzola,et al.  Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. , 2005, European heart journal.

[326]  Grkat Ves,et al.  A Treatise on the Diseases of the Heart and Great Vessels , 1832, The Medico-chirurgical review.

[327]  D. Karageorgopoulos,et al.  Etiology of anemia in patients with advanced heart failure. , 2006, Journal of the American College of Cardiology.

[328]  B. Ewald,et al.  Meta‐analysis of B type natriuretic peptide and N‐terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction , 2008, Internal medicine journal.

[329]  Salim Yusuf,et al.  Effectiveness of comprehensive disease management programmes in improving clinical outcomes in heart failure patients. A meta‐analysis , 2005, European journal of heart failure.

[330]  L. Stevenson,et al.  Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial , 2011, The Lancet.

[331]  Alan S Maisel,et al.  Cardiac biomarkers: a contemporary status report , 2006, Nature Clinical Practice Cardiovascular Medicine.

[332]  S. Anker,et al.  Cachexia in chronic heart failure: Prognostic implications and novel therapeutic approaches , 2005, Current heart failure reports.

[333]  Daniel Levy,et al.  Long-term trends in the incidence of and survival with heart failure. , 2002, The New England journal of medicine.

[334]  E. Minder,et al.  Single-chamber ventricular pacing increases markers of left ventricular dysfunction compared with dual-chamber pacing. , 2007, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[335]  J. Moran,et al.  Effect of non-invasive positive pressure ventilation (NIPPV) on mortality in patients with acute cardiogenic pulmonary oedema: a meta-analysis , 2006, The Lancet.

[336]  N. Lamblin,et al.  Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. , 2004, European heart journal.

[337]  J. Beizer,et al.  Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. , 2005, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.

[338]  K. Dickstein,et al.  Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial , 2009, The Lancet.

[339]  J. Murabito,et al.  Lifetime Risk for Developing Congestive Heart Failure: The Framingham Heart Study , 2002, Circulation.

[340]  H. Riess,et al.  Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study. , 2011, American heart journal.

[341]  Stephan von Haehling,et al.  Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. , 2007, Cardiovascular research.

[342]  J. Cohn,et al.  Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. , 1992, American heart journal.

[343]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[344]  A. Strömberg,et al.  European Society of Cardiology Heart Failure Association Standards for delivering heart failure care , 2011, European journal of heart failure.

[345]  Akshay S. Desai,et al.  Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. , 2005, JAMA.

[346]  John Wikstrand,et al.  Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients with Heart Failure: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) , 2000 .

[347]  Shunichi Homma,et al.  Warfarin and aspirin in patients with heart failure and sinus rhythm. , 2012, The New England journal of medicine.

[348]  Fibrinolytic Therapy Trialists' Collaborative Group.  Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994, The Lancet.

[349]  N. Christensen,et al.  Neuroendocrine testing in community patients with heart disease: plasma N-terminal proatrial natriuretic peptide predicts morbidity and mortality stronger than catecholamines and heart rate variability , 2004, Scandinavian journal of clinical and laboratory investigation.

[350]  Joanne Brown,et al.  Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. , 2008, Journal of the American College of Cardiology.

[351]  Eric Boersma,et al.  Effects of cardiac resynchronization therapy on overall mortality and mode of death: a meta-analysis of randomized controlled trials. , 2006, European heart journal.

[352]  L. Shaw,et al.  Journal of Cardiovascular Magnetic Resonance Clinical Indications for Cardiovascular Magnetic Resonance (cmr): Consensus Panel Report , 2022 .

[353]  J. Daubert,et al.  Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. , 2002, European heart journal.

[354]  K. Swedberg,et al.  Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. , 2004, Journal of the American College of Cardiology.

[355]  V. Roger,et al.  Trends in prevalence and outcome of heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.

[356]  P. Hildebrandt,et al.  Diagnostic and prognostic performance of N-terminal ProBNP in primary care patients with suspected heart failure. , 2005, Journal of cardiac failure.

[357]  J. Hoffman,et al.  Comparison of nitroglycerin, morphine and furosemide in treatment of presumed pre-hospital pulmonary edema. , 1987, Chest.

[358]  L. Stevenson,et al.  Ventricular assist devices for durable support. , 2005, Circulation.

[359]  Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative , 2009, European heart journal.

[360]  K. Swedberg,et al.  Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. , 2007, JAMA.

[361]  A. Habets,et al.  Defibrillator implantation early after myocardial infarction. , 2009, The New England journal of medicine.

[362]  Stuart Russell,et al.  Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates--2006. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[363]  P A Poole-Wilson,et al.  Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. , 1999, Circulation.

[364]  J. Ornato,et al.  [ACC/AHA/ESC 2006 guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary]. , 2006, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[365]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[366]  I. Squire,et al.  Prognosis for patients newly admitted to hospital with heart failure: survival trends in 12 220 index admissions in Leicestershire 1993–2001 , 2003, Heart.

[367]  D. DeMets,et al.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. , 2004, The New England journal of medicine.

[368]  Wojciech Zareba,et al.  Cardiac-resynchronization therapy for the prevention of heart-failure events. , 2009, The New England journal of medicine.

[369]  Eloisa Arbustini,et al.  Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2007, European heart journal.

[370]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[371]  P. Poole‐Wilson,et al.  Clinical importance of the renin-angiotensin system in chronic heart failure: double blind comparison of captopril and prazosin. , 1985, British medical journal.

[372]  J. McMurray,et al.  The acute vascular effects of frusemide in heart failure. , 2000, British journal of clinical pharmacology.

[373]  M. Gheorghiade,et al.  Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. , 2005, The American journal of cardiology.

[374]  Juerg Schwitter,et al.  Recommendations for cardiovascular magnetic resonance in adults with congenital heart disease from the respective working groups of the European Society of Cardiology , 2010, European heart journal.

[375]  E. J. Brown,et al.  The effect of digoxin on mortality and morbidity in patients with heart failure. , 1997, The New England journal of medicine.

[376]  Luigi Tavazzi,et al.  Acute Heart Failure Syndromes: Current State and Framework for Future Research , 2005, Circulation.

[377]  P. Sanders,et al.  Role of AV nodal ablation in cardiac resynchronization in patients with coexistent atrial fibrillation and heart failure a systematic review. , 2012, Journal of the American College of Cardiology.

[378]  H. Galley.  Renal-dose dopamine: will the message now get through? , 2000, The Lancet.

[379]  H L Greene,et al.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.

[380]  W. Kannel,et al.  The natural history of congestive heart failure: the Framingham study. , 1971, The New England journal of medicine.

[381]  D. Levy,et al.  Natural History of Asymptomatic Left Ventricular Systolic Dysfunction in the Community , 2003, Circulation.

[382]  J. Rouleau,et al.  Neurohormones and oxidative stress in nonischemic cardiomyopathy: relationship to survival and the effect of treatment with amlodipine. , 2003, American heart journal.

[383]  M. Picard,et al.  NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy. , 2006, European heart journal.

[384]  J. Hampton,et al.  Comparison of the effects of captopril and enoximone in patients with severe heart failure: a placebo controlled double-blind study. , 1989, International journal of cardiology.

[385]  K. Dimopoulos,et al.  Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: a combined retrospective and case-control study. , 2006, European heart journal.

[386]  F. Morady,et al.  Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--AMIOVIRT. , 2003, Journal of the American College of Cardiology.

[387]  K. Lee,et al.  A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. , 1999, The New England journal of medicine.

[388]  Michael Böhm,et al.  Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology , 2007, European journal of heart failure.

[389]  J. Rogers,et al.  Patient selection for left ventricular assist devices. , 2011, Congestive heart failure.

[390]  Harlan M Krumholz,et al.  Randomized trial of an education and support intervention to prevent readmission of patients with heart failure. , 2002, Journal of the American College of Cardiology.

[391]  S. Czajkowski,et al.  The effect of digoxin on the quality of life in patients with heart failure. , 2003, Journal of cardiac failure.

[392]  A. DeMaria,et al.  Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction , 2001 .

[393]  N. Freemantle,et al.  Perindopril for elderly people with chronic heart failure: the PEP‐CHF study , 1999, European heart journal.

[394]  P. Poole‐Wilson,et al.  Coronary artery disease as the cause of incident heart failure in the population. , 2001, European heart journal.

[395]  P C Deedwania,et al.  Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. , 1995, The New England journal of medicine.

[396]  P. Kolh,et al.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, European heart journal.

[397]  P. Poole‐Wilson,et al.  Exercise limitation in chronic heart failure: central role of the periphery. , 1996, Journal of the American College of Cardiology.

[398]  David O. Martin,et al.  Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. , 2008, The New England journal of medicine.

[399]  C M O'Connor,et al.  Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. , 1996, The New England journal of medicine.

[400]  K. Dickstein,et al.  [Executive summary of the guidelines on the diagnosis and treatment of acute heart failure]. , 2005, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[401]  Scott Lim,et al.  Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort. , 2009, Journal of the American College of Cardiology.

[402]  Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1987, The New England journal of medicine.

[403]  E. Salpeter,et al.  Cardioselective beta-blockers for chronic obstructive pulmonary disease. , 2005, The Cochrane database of systematic reviews.

[404]  Fibrinolytictherapytrialistsf.  Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .

[405]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[406]  Stuart J Pocock,et al.  Transcatheter versus surgical aortic-valve replacement in high-risk patients. , 2011, The New England journal of medicine.

[407]  K. Swedberg,et al.  Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. , 2007, JAMA.

[408]  D. Leong,et al.  eart Failure With Normal Ejection Fraction : he Complementary Roles of Echocardiography nd CMR Imaging arryl , 2022 .

[409]  Nader Moazami,et al.  Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. , 2009, Journal of the American College of Cardiology.

[410]  A. Cohen-Solal,et al.  Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. , 2007, JAMA.

[411]  O H Frazier,et al.  Use of a continuous-flow device in patients awaiting heart transplantation. , 2007, The New England journal of medicine.

[412]  T. Edvardsen,et al.  Echocardiographic Evaluation of Hemodynamics in Patients With Decompensated Systolic Heart Failure , 2011, Circulation. Cardiovascular imaging.

[413]  M C Oz,et al.  Long-term use of a left ventricular assist device for end-stage heart failure. , 2001, The New England journal of medicine.

[414]  William Wijns,et al.  [Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes]. , 2007, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[415]  G. Jondeau,et al.  B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. , 2009, European heart journal.

[416]  Gerasimos S Filippatos,et al.  Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation , 2011, European journal of heart failure.

[417]  James B. Young.  Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial , 2002 .

[418]  S. Marsch,et al.  Use of B-type natriuretic peptide for the management of women with dyspnea. , 2004, The American journal of cardiology.

[419]  D. Atar,et al.  Dronedarone in high-risk permanent atrial fibrillation. , 2011, The New England journal of medicine.

[420]  T. Lauer,et al.  Kardiologische Aspekte der präoperativen Risikostratifizierung , 2011 .

[421]  Milton Packer,et al.  Cardiac resynchronization in chronic heart failure. , 2002, The New England journal of medicine.

[422]  S. Yusuf,et al.  Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. , 2005, JAMA.

[423]  J. McMurray,et al.  Increased mortality after dronedarone therapy for severe heart failure. , 2008, The New England journal of medicine.

[424]  K. Hammermeister,et al.  Implications of third heart sounds in patients with valvular heart disease. The Veterans Affairs Cooperative Study on Valvular Heart Disease. , 1992, The New England journal of medicine.

[425]  O. Alfieri,et al.  [Guidelines on the management of valvular heart disease (version 2012). The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)]. , 2013, Giornale italiano di cardiologia.

[426]  G. Filippatos,et al.  Prognosis and therapy approaches of cardiac cachexia , 2006, Current opinion in cardiology.

[427]  C. Witt,et al.  Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. , 2003, American heart journal.

[428]  Eric Fain,et al.  Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. , 2004, The New England journal of medicine.

[429]  Karel G M Moons,et al.  Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study , 2005, BMJ : British Medical Journal.

[430]  S. Yusuf,et al.  Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure , 1995 .

[431]  K. Kuck,et al.  Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). , 1994, American heart journal.

[432]  O. Simonetti,et al.  The CMR examination in heart failure. , 2009, Heart failure clinics.

[433]  P. Ponikowski,et al.  Wasting as independent risk factor for mortality in chronic heart failure , 1997, The Lancet.

[434]  J. McMurray,et al.  Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology , 2009, European journal of heart failure.

[435]  S. Connolly,et al.  Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT , 1997, The Lancet.

[436]  J. Daubert,et al.  The effect of cardiac resynchronization on morbidity and mortality in heart failure. , 2005, The New England journal of medicine.

[437]  R. McKelvie,et al.  Diabetes, left ventricular systolic dysfunction, and chronic heart failure. , 2008, European heart journal.

[438]  D. J. Veldhuisen,et al.  Non‐compliance in patients with heart failure; how can we manage it? , 2005, European journal of heart failure.

[439]  W. Kraus,et al.  Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. , 2009, JAMA.

[440]  A. Camm,et al.  Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. , 1999, The New England journal of medicine.

[441]  J. Schwitter.  Extending the frontiers of cardiac magnetic resonance. , 2008, Circulation.

[442]  C. Specchia,et al.  The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT‐proBNP and cardiac troponin‐T , 2007, European journal of heart failure.

[443]  Diederick E Grobbee,et al.  Quantifying the added value of BNP in suspected heart failure in general practice: an individual patient data meta-analysis , 2011, Heart.

[444]  Haya R Rubin,et al.  Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis. , 2004, JAMA.

[445]  F. Rutten,et al.  Heart failure and chronic obstructive pulmonary disease: An ignored combination? , 2006, European journal of heart failure.

[446]  J. Cohn,et al.  Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. , 2002, Journal of the American College of Cardiology.

[447]  J. Daubert,et al.  Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. , 2006, European heart journal.

[448]  G. Filippatos,et al.  An introduction to acute heart failure syndromes: definition and classification , 2007, Heart Failure Reviews.

[449]  Susan Anderson,et al.  Irbesartan in patients with heart failure and preserved ejection fraction. , 2008, The New England journal of medicine.

[450]  Marvin A. Konstam,et al.  Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction--pharmacological approaches. , 1999, Journal of cardiac failure.

[451]  A. Cohen-Solal,et al.  Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). , 2005, European heart journal.

[452]  Arturo Evangelista,et al.  Recommendations for the evaluation of left ventricular diastolic function by echocardiography. , 2009, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[453]  A. Strömberg,et al.  Development and testing of the European Heart Failure Self‐Care Behaviour Scale , 2003, European journal of heart failure.

[454]  J. McMurray,et al.  Potentially detrimental cardiovascular effects of oxygen in patients with chronic left ventricular systolic dysfunction , 2010, Heart.

[455]  C. O'connor,et al.  Coronary-artery bypass surgery in patients with left ventricular dysfunction. , 2011, The New England journal of medicine.

[456]  Theresa McDonagh,et al.  UK guidelines for referral and assessment of adults for heart transplantation , 2011, Heart.

[457]  F. Tristani,et al.  Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study. , 1982, The New England journal of medicine.

[458]  A. Cohen-Solal,et al.  Clinical profile, contemporary management and one‐year mortality in patients with severe acute heart failure syndromes: The EFICA study ☆ , 2006, European journal of heart failure.

[459]  Y. Moshkovitz,et al.  Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema , 1998, The Lancet.

[460]  Samuel Wann,et al.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committ , 2006, European heart journal.

[461]  GISSI-Prevenzione Investigators,et al.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial , 1999, The Lancet.

[462]  Barry J Maron,et al.  Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interd , 2006, Circulation.

[463]  A. Hoes,et al.  Added value of a physician-and-nurse-directed heart failure clinic: results from the Deventer–Alkmaar heart failure study , 2006, Heart.

[464]  A. Turpie,et al.  Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study , 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[465]  P. Presbitero,et al.  Eisenmenger syndrome. Factors relating to deterioration and death. , 1998, European heart journal.

[466]  M Gent,et al.  Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. , 2000, Circulation.

[467]  C. O'connor,et al.  Anemia as a risk factor and therapeutic target in heart failure. , 2004, Journal of the American College of Cardiology.

[468]  Christopher M O'Connor,et al.  Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. , 2003, Journal of the American College of Cardiology.

[469]  S. Myerson.  Valvular and hemodynamic assessment with CMR. , 2009, Heart failure clinics.

[470]  K. Swedberg,et al.  Exploring symptoms in chronic heart failure , 2005, European journal of heart failure.

[471]  Harlan M Krumholz,et al.  National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. , 2011, JAMA.

[472]  M. Clearfield.  Rosuvastatin in older patients with systolic heart failure. , 2009, Current atherosclerosis reports.

[473]  Gissi-Hf Investigators.  Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[474]  M. Pfeffer,et al.  Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial , 2005, The Lancet.

[475]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[476]  K. Swedberg,et al.  [Expert Consensus document on beta-adrenergic receptor blockers]. , 2004, Revista espanola de cardiologia.

[477]  K. Bailey,et al.  Congestive heart failure in the community: trends in incidence and survival in a 10-year period. , 1999, Archives of internal medicine.

[478]  J. McMurray,et al.  Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial , 2010, Heart.

[479]  F. Sarullo,et al.  Normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend? , 2008, Clinical science.

[480]  Karl Swedberg,et al.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.

[481]  R. Ferrari,et al.  Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[482]  Inger Ekman,et al.  Reasons for seeking acute care in chronic heart failure , 2007, European journal of heart failure.

[483]  Renu Virmani,et al.  A Scientific Statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology , 2022 .

[484]  M. Flather,et al.  Overview of studies of exercise training in chronic heart failure: the need for a prospective randomized multicentre European trial. , 1998, European heart journal.

[485]  C. Frampton,et al.  Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.

[486]  G. D. De Keulenaer,et al.  Diastolic heart failure: a myth. , 2006, Current opinion in cardiology.

[487]  P. Poole‐Wilson,et al.  Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial , 2003, The Lancet.

[488]  A. Hungin,et al.  The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. , 2006, The British journal of general practice : the journal of the Royal College of General Practitioners.

[489]  E. Topol,et al.  Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndromes: the enduring value of Killip classification. , 2003, JAMA.

[490]  T Douglas Bradley,et al.  Obstructive sleep apnea and heart failure: pathophysiologic and therapeutic implications. , 2011, Journal of the American College of Cardiology.

[491]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.